Table 3.
ODs and ED for (+)-[18F]flubatine based on human data
| Target organ | OD | SD | ED contribution | SD |
|---|---|---|---|---|
| (mSv/MBq) | (mSv/MBq) | |||
| Adrenals | 1.30E−02 | 2.26E−03 | 1.12E−04 | 1.94E−05 |
| Brain | 2.86E−02 | 3.33E−03 | 2.86E−04 | 3.33E−05 |
| Breasts | 6.29E−03 | 3.86E−04 | 7.55E−04 | 4.63E−05 |
| Gallbladder wall | 2.34E−02 | 9.30E−03 | 2.01E−04 | 7.99E−05 |
| LLI wall | 1.67E−02 | 2.89E−03 | 1.00E−03 | 1.74E−04 |
| Small intestine | 2.94E−02 | 8.90E−03 | 2.53E−04 | 7.66E−05 |
| Stomach wall | 2.04E−02 | 3.89E−03 | 2.44E−03 | 4.67E−04 |
| ULI wall | 3.24E−02 | 1.02E−02 | 1.94E−03 | 6.14E−04 |
| Heart wall | 1.57E−02 | 1.65E−03 | 1.35E−04 | 1.42E−05 |
| Kidneys | 3.81E−02 | 4.52E−03 | 3.28E−04 | 3.89E−05 |
| Liver | 5.31E−02 | 2.98E−02 | 2.12E−03 | 1.19E−03 |
| Lungs | 2.70E−02 | 2.60E−03 | 3.24E−03 | 3.12E−04 |
| Muscle | 7.90E−03 | 1.26E−04 | 6.80E−05 | 1.08E−06 |
| Ovaries | 1.31E−02 | 1.22E−03 | 1.05E−03 | 9.73E−05 |
| Pancreas | 2.08E−02 | 4.11E−03 | 1.79E−04 | 3.53E−05 |
| Red marrow | 1.49E−02 | 8.50E−04 | 1.79E−03 | 1.02E−04 |
| Osteogenic cells | 1.42E−02 | 7.81E−04 | 1.42E−04 | 7.81E−06 |
| Skin | 5.52E−03 | 1.27E−04 | 5.52E−05 | 1.27E−06 |
| Spleen | 1.34E−02 | 4.19E−03 | 1.15E−04 | 3.60E−05 |
| Testes | 2.17E−02 | 1.21E−02 | 1.53E−03 | 1.33E−03 |
| Thymus | 7.48E−03 | 2.91E−04 | 6.43E−05 | 2.50E−06 |
| Thyroid | 2.29E−02 | 4.37E−03 | 9.17E−04 | 1.75E−04 |
| Urinary bladder wall | 1.02E−01 | 2.96E−02 | 4.09E−03 | 1.18E−03 |
| Uterus | 1.55E−02 | 1.71E−03 | 1.33E−04 | 1.47E−05 |
| Total body | 1.05E−02 | 8.42E−04 | – | – |
| ED (mSv/MBq) | 2.30E−02 | 1.91E−03 | ||
| ED (mSv/MBq) ICRP 60 | 2.48E−02 | 1.18E−03 | ||
ODs calculated for the adult male model (73.7 kg, implemented in OLINDA)
OD organ dose, ED effective dose (ICRP 103), SD standard deviation mean over three human subjects